Adial Pharmaceuticals, based in Charlottesville, VA, is a clinical-stage biopharmaceutical company specializing in the development of treatments for addictions and other unmet medical needs. Their lead investigational drug candidate, AD04, is a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD), currently undergoing a pivotal Phase 3 clinical trial.
Under the leadership of CEO Cary Claiborne, Adial Pharmaceuticals is focused on advancing precision medicine approaches in the treatment of AUD, with a key emphasis on developing non-abstinence-based therapies. The company's innovative research and commitment to addressing the challenges of addiction highlight their dedication to improving patient outcomes in the field of biopharmaceuticals.
Generated from the website